The role of machine learning in centralized authorization process of nanomedicines in European Union

Ricardo Santana, Onieva, Zuluaga, Duardo-Sánchez, Gañán

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

1 Cita (Scopus)

Resumen

Background: Machine Learning (ML) has experienced an increasing use, given the possibilities to expand the scientific knowledge of different disciplines, such as nanotechnology. This has allowed the creation of Cheminformatic models capable of predicting biological activity and physicochemical characteristics of new components with high success rates in training and test partitions. Given the current gaps of scientific knowledge and the need for efficient application of medicines products law, this paper analyzes the position of regulators for marketing medicinal nanoproducts in the European Union and the role of ML in the authorization process. Methods: In terms of methodology, a dogmatic study of the European regulation and the guidance of the European Medicine Agency on the use of predictive models for nanomaterials was carried out. The study has, as the framework of reference, the European Regulation 726/2004 and has focused on the analysis of how ML processes are contemplated in the regulations. Results: As a result, we present a discussion of the information that must be provided for every case for simulation methods. The results show a favorable and flexible position for the development of the use of predictive models to complement the applicant's information. Conclusion: It is concluded that Machine Learning has the capacity to help improve the application of nanotechnology medicine products regulation. Future regulations should promote this kind of information given the advanced state of the art in terms of algorithms that are able to build accurate predictive models. This especially applies to methods, such as Perturbation Theory Machine Learning (PTML), given that it is aligned with principles promoted by the standards of Organization for Economic Co-operation and Development (OECD), European Union regulations, and European Authority Medicine. To our best knowledge, this is the first study focused on nanotechnology medicine products and machine learning used to support technical European public assessment reports (EPAR) for complementary information.

Idioma originalInglés
Páginas (desde-hasta)828-838
Número de páginas11
PublicaciónCurrent Topics in Medicinal Chemistry
Volumen21
N.º9
DOI
EstadoPublicada - abr. 2021

Nota bibliográfica

Publisher Copyright:
© 2021 Bentham Science Publishers.

Huella

Profundice en los temas de investigación de 'The role of machine learning in centralized authorization process of nanomedicines in European Union'. En conjunto forman una huella única.

Citar esto